Regeneron antibody cocktail lowers virus in Covid-19 patients

Biopharma company is hiring 400 new workers at its Limerick facility
Regeneron antibody cocktail lowers virus in Covid-19 patients

Regeneron's treatment contains a mix of two highly potent antibodies against the coronavirus spike protein. Picture: George Frey/Bloomberg

A Regeneron Pharmaceuticals antibody cocktail may help treat coronavirus patients outside of the hospital by reducing virus levels and symptoms, early study results indicate.

In an early-stage clinical trial of 275 Covid-19 patients, those who received Regeneron’s experimental therapy had lower virus levels in the bloodstream seven days later compared with patients who received a placebo, the company said in a statement.

Announcing 400 new jobs at Regeneron in Raheen, Limerick, were; Niall O’Leary, Vice President and Site Head, Regeneron; Tánaiste Leo Varadkar TD; An Taoiseach Micheál Martin TD; and Mary Buckley, Executive Director IDA. Picture: Cathal Noonan
Announcing 400 new jobs at Regeneron in Raheen, Limerick, were; Niall O’Leary, Vice President and Site Head, Regeneron; Tánaiste Leo Varadkar TD; An Taoiseach Micheál Martin TD; and Mary Buckley, Executive Director IDA. Picture: Cathal Noonan

The biopharmaceutical company has a large operation in Limerick where it is adding more than 400 jobs in order to maximise capacity at its New York facility to produce large quantities of the Covid treatment.

Regeneron’s treatment, which contains a mix of two highly potent antibodies against the coronavirus spike protein, “rapidly reduced viral load and associated symptoms in infected Covid-19 patients,” George D. Yancopoulos, Regeneron’s chief scientific officer, said in the statement. 

“The greatest treatment benefit was in patients who had not mounted their own effective immune response.” The results are a sign that experimental antibody treatments could become a powerful part of the arsenal for treating the coronavirus. Anthony Fauci, the top US infectious-disease official, has referred to antibody-based medicines that could treat infected patients sooner after they contract the virus as a bridge to a vaccine.

Several companies are developing similar therapies. Earlier this month, Eli Lilly & Co. said its experimental antibody treatment reduced the rate at which symptomatic coronavirus patients were hospitalized compared with a placebo. Other companies testing antibody treatments include AstraZeneca Plc, as well as GlaxoSmithKline Plc and its partner Vir Biotechnology Inc.

Regeneron said its therapy appeared to be most beneficial in the subset of patients who hadn’t yet produced coronavirus antibodies on their own. In those patients, symptoms eased 8 days after they received a high dose of the cocktail, called REGN-COV2, compared with 13 days in antibody-negative patients who received a placebo.

Both high and low doses were well-tolerated, Regeneron said.

A much larger part of the trial that will generate definitive efficacy results plans to enroll 1,300 outpatient coronavirus sufferers. In addition, Tarrytown, New York-based Regeneron is studying the therapy in hospitalized patients and also as a preventative in household contacts of infected individuals.

Bloomberg

More in this section

Lunchtime News Wrap

A lunchtime summary of content highlights on the Irish Examiner website. Delivered at 1pm each day.

Sign up
Revoiced
Newsletter

Our Covid-free newsletter brings together some of the best bits from irishexaminer.com, as chosen by our editor, direct to your inbox every Monday.

Sign up